CLEVELAND, May 03, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) (“Abeona” or the “Company”) today announced the pricing of an underwritten offering of 12,285,056 shares of its common stock and, in lieu of common stock, pre-funded warrants to purchase 6,142,656 shares of its common stock, at an offering price of $4.07 per share, which is equal to the closing price on Thursday, May 2, 2024, or $4.0699 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.0001 per share exercise price for each pre-funded warrant.

克利夫兰，2024年5月3日（环球通讯社）--Abeona Therapeutics Inc。（纳斯达克：ABEO）（“Abeona”或“公司”）今天宣布，以每股4.07美元的发行价格（相当于2024年5月2日星期四的收盘价，即每股4.0699美元的预付款认股权证）对其12285056股普通股的承销发行进行定价，并代替普通股，购买6142656股普通股的预付款认股权证，发行价格为每股4.07美元，即每股预付款认股权证的4.0699美元，即普通股每股发行价格减去每股预付款认股权证的0.0001美元行权价格。

The pre-funded warrants will be immediately exercisable at a nominal exercise price of $0.0001 per share and may be exercised at any time until the pre-funded warrants are exercised in full. The closing of the offering is expected to occur on or about May 7, 2024, subject to the satisfaction of customary closing conditions..

预先出资的认股权证将立即以每股0.0001美元的名义行权价格行权，并可随时行权，直到预先出资的认股权证全部行权。预计本次发行将于2024年5月7日左右结束，但须满足常规交割条件。。

The offering included participation from both new and existing investors, including Adage Capital Partners, L.P., Janus Henderson Investors, Nantahala Capital, Suvretta Capital, Vivo Capital, and other healthcare-dedicated investors.

此次发行包括新投资者和现有投资者的参与，包括Adage Capital Partners，L.P.，Janus Henderson investors，Nantahala Capital，Suvretta Capital，Vivo Capital和其他医疗保健专业投资者。

Stifel is acting as the sole bookrunner for the offering.

Stifel是此次发售的唯一账簿管理人。

The gross proceeds to Abeona from this offering are expected to be approximately $75 million, before deducting underwriting discounts and commissions and other offering expenses. Abeona intends to use the net proceeds from the offering primarily to fund preparations for resubmission of its BLA and for commercialization of its product candidate pz-cel, as well as for working capital and general corporate purposes..

在扣除承销折扣、佣金和其他发行费用之前，预计此次发行给Abeona的总收益约为7500万美元。Abeona打算将此次发售的净收益主要用于重新提交其BLA的准备工作、候选产品pz cel的商业化以及营运资金和一般企业用途。。

The securities described above are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333-256850) that was filed with the Securities and Exchange Commission (the “SEC”) on June 7, 2021 and amended on August 27, 2021 and October 19, 2021, and was declared effective by the SEC on October 22, 2021.

上述证券是根据表S-3（文件号333-256850）上的货架登记声明发行的，该声明于2021年6月7日提交给证券交易委员会（“SEC”），并于2021年8月27日和2021年10月19日修订，并于2021年10月22日由SEC宣布生效。

When available, the prospectus supplement and the accompanying prospectus that form a part of the registration statement will be filed with the SEC and available on the SEC’s website at www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus may also be obtained when available by contacting Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com..

招股说明书补充资料和随附招股说明书（构成注册声明的一部分）将在美国证券交易委员会备案，并可在美国证券交易委员会的网站www.SEC.gov上查阅。如果可以通过联系Stifel，Nicolaus&Company，Incorporated，收件人：招股说明书部，One Montgomery Street，Suite 3700，San Francisco，CA 94104，电话：（415）364-2720或电子邮件syndprospectus@stifel.com..

The securities described above have not been qualified under any state blue sky laws. This press release does not constitute an offer to sell or the solicitation of offers to buy any securities of Abeona being offered, and shall not constitute an offer, solicitation or sale of any security in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction..

上述证券不符合任何州蓝天法律的规定。本新闻稿不构成出售阿贝欧纳任何证券的要约或购买阿贝欧纳任何证券的要约征集，也不构成在任何州或司法管辖区的任何证券的要约、征集或出售，在根据任何州或司法管辖区的证券法登记或取得资格之前，该等要约、征集或出售将是非法的。。

About Abeona Therapeutics

关于Abeona Therapeutics

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Prademagene zamikeracel (pz-cel) is Abeona’s investigational autologous, COL7A1 gene-corrected epidermal sheets currently in development for recessive dystrophic epidermolysis bullosa.

Abeona Therapeutics Inc.是一家临床阶段的生物制药公司，开发针对严重疾病的细胞和基因疗法。Prademagene zamikeracel（pz-cel）是Abeona的研究性自体COL7A1基因校正表皮片，目前正在开发隐性营养不良性大疱性表皮松解症。

The Company’s fully integrated cell and gene therapy cGMP manufacturing facility served as the manufacturing site for pz-cel used in its Phase 3 VIITAL™ trial, and is capable of supporting commercial production of pz-cel if FDA approval is obtained. The Company’s development portfolio also features AAV-based gene therapies for ophthalmic diseases with high unmet medical need.

该公司的完全集成的细胞和基因治疗cGMP生产设施是其3期VIITAL™试验中使用的pz-cel的生产基地，如果获得FDA批准，则能够支持pz-cel的商业生产。该公司的开发组合还包括基于AAV的基因疗法，用于高度未满足医疗需求的眼科疾病。

Abeona’s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases..

Abeona的新型下一代AAV衣壳正在进行评估，以改善各种毁灭性疾病的趋向性。。

Forward-Looking Statements

前瞻性声明

This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempted to identify forward-looking statements by such terminology as “may,” “will,” “believe,” “anticipate,” “expect,” “intend,” “potential,” and similar words and expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements.

本新闻稿包含经修订的《1933年证券法》第27A节和经修订的《1934年证券交易法》第21E节所指的前瞻性声明，并涉及风险和不确定性。我们试图通过“可能”、“将”、“相信”、“预期”、“预期”、“打算”、“潜在”等术语以及类似的词语和表达（以及其他涉及未来事件、条件或情况的词语或表达）来识别前瞻性陈述，这些词语构成并旨在识别前瞻性陈述。

Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including, but not limited to, the satisfaction of customary closing conditions related to the offering; the timing and outcome of the Company’s Biologics License Application submission to the FDA for pz-cel, including as related to the Complete Response Letter received from the FDA; potential market opportunities and commercial launch strategies for pz-cel, if approved; the FDA’s grant of a Priority Review Voucher; continued interest in the Company’s rare disease portfolio; the timing of studies or study manuscript submissions; the Company’s ability to enroll patients in clinical trials; the outcome of future meetings with the FDA or other regulatory agencies, including those relating to preclinical programs; the ability to achieve or obtain necessary regulatory approvals; the impact of any changes in the financial markets and global economic conditions; risks relating to the recent decline in market price of the Company’s common stock in response to the Complete Response Letter; risks associated wi.

由于各种重要因素、众多风险和不确定性，包括但不限于满足与发行相关的惯例交割条件，实际结果可能与此类前瞻性声明所示的结果存在重大差异；公司向FDA提交pz cel生物制剂许可证申请的时间和结果，包括与FDA收到的完整回复信有关的时间和结果；如果获得批准，pz cel的潜在市场机会和商业启动策略；FDA授予优先审查凭证；对公司罕见病投资组合的持续兴趣；研究或研究稿件提交的时间；公司招募患者参加临床试验的能力；与FDA或其他监管机构（包括与临床前计划有关的机构）未来会议的结果；获得或获得必要监管批准的能力；金融市场和全球经济状况的任何变化的影响；与公司普通股市场价格近期下跌相关的风险，以回应完整的回复函；与wi相关的风险。

Investor and Media Contact:

投资者和媒体联系人：

Greg Gin

格雷格·金

VP, Investor Relations and Corporate Communications

投资者关系和企业传播副总裁

Abeona Therapeutics

Abeona治疗学

ir@abeonatherapeutics.com

ir@abeonatherapeutics.com